[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3328
1. Williams G, Foyle A, White D, Greer W, Burrell S, Couban S: Intravascular T-cell lymphoma with bowel involvement: case report and literature review. Am J Hematol; 2005 Mar;78(3):207-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular T-cell lymphoma with bowel involvement: case report and literature review.
  • Intravascular lymphoma (IVL) is a rare form of non-Hodgkin lymphoma characterized by massive proliferation of large, neoplastic cells in small- and medium-sized blood vessels.
  • In 4 of 5 cases, patients died of lymphoma within 3 months of presentation; one patient experienced a 10-month remission.
  • [MeSH-major] Colon / pathology. Lymphoma, T-Cell / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Colostomy. Female. Humans. Ileostomy. Intestinal Mucosa / blood supply. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726592.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Zeytinoğlu A, Hekimgil M, Erensoy S, Aydemir S, Berber S, Cağirgan S, Soydan S, Bilgiç A: [Investigation of Epstein-Barr virus DNA and RNA in tissues of patients with lymphoma]. Mikrobiyol Bul; 2005 Oct;39(4):473-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation of Epstein-Barr virus DNA and RNA in tissues of patients with lymphoma].
  • Relation between Epstein-Barr virus (EBV) and nasopharyngeal carsinoma, Burkitt's lymphoma, and lymphomas in immunosupressed patients have been shown previously in different studies.
  • The same relationship was also shown in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) by some researchers.
  • The aim of this study was to demonstrate EBV nucleic acids in tissue sections of adult patients with lymphoma.
  • [MeSH-major] DNA, Viral / isolation & purification. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology. Lymphoma, Non-Hodgkin / virology. RNA, Viral / isolation & purification
  • [MeSH-minor] Adolescent. Adult. Aged. Humans. In Situ Hybridization. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16544549.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


3. Ling JY, Sun XF, Zhang X, Zhen ZJ, Xia Y, Luo WB, Lin H, Zheng L: [Dynamic changes of serum proteomic spectra in patients with non-Hodgkin's lymphoma (NHL) before and after chemotherapy and screening of candidate biomarkers for NHL]. Ai Zheng; 2008 Oct;27(10):1065-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dynamic changes of serum proteomic spectra in patients with non-Hodgkin's lymphoma (NHL) before and after chemotherapy and screening of candidate biomarkers for NHL].
  • BACKGROUND & OBJECTIVE: Although the complete response rate of non-Hodgkin's lymphoma (NHL) is 70%-80% using modern comprehensive treatments, its relapse rate is about 40%-50%.
  • The minimal residual disease (MRD) may be the reason of recurrence.
  • [MeSH-major] Biomarkers, Tumor / blood. Gene Expression Profiling. Lymphoma, Non-Hodgkin / blood. Proteome / analysis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Decision Trees. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual / blood. Protein Array Analysis. Remission Induction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18851786.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


Advertisement
4. Hodgson DC, Pintilie M, Gitterman L, Dewitt B, Buckley CA, Ahmed S, Smith K, Schwartz A, Tsang RW, Crump M, Wells W, Sun A, Gospodarowicz MK: Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol; 2007 Mar;25(1):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Fertility / drug effects. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / therapeutic use. Case-Control Studies. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Pregnancy. Pregnancy Rate. Surveys and Questionnaires. Survivors. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036376.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


5. Jose BO, Koerner P, Spanos WJ Jr, Paris KJ, Silverman CL, Yashar C, Carrascosa LB: Hodgkin's lymphoma in adults--clinical features. J Ky Med Assoc; 2005 Jan;103(1):15-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in adults--clinical features.
  • Nineteen percent (19%) of the patients were older and this was similar to the reported bimodal pattern in Hodgkin's disease.
  • Thirty-one percent (31%) of the patients presented with one or more of the 'B' symptoms as described by Cotswolds Staging Classification for Hodgkin's Disease.
  • Thirty-three percent (33%) of the patients had bulky mediastinal disease.
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Female. Head and Neck Neoplasms / epidemiology. Humans. Kentucky / epidemiology. Male. Mediastinal Neoplasms / epidemiology. Middle Aged

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682982.001).
  • [ISSN] 0023-0294
  • [Journal-full-title] The Journal of the Kentucky Medical Association
  • [ISO-abbreviation] J Ky Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


6. Bhagavathi S, Wilson JD: Primary central nervous system lymphoma. Arch Pathol Lab Med; 2008 Nov;132(11):1830-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an uncommon extranodal non-Hodgkin lymphoma.
  • Diffuse large B-cell lymphomas constitute most PCNSLs, whereas T-cell, low-grade, anaplastic, and Hodgkin lymphomas are rarely encountered.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976024.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


7. Qiao W, Zhao J, Wang C, Wang T, Xing Y: Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Hematology; 2010 Feb;15(1):21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
  • OBJECTIVE: Evaluation of therapeutic response in non-Hodgkin's lymphoma (NHL) patients with autologous stem cell transplantation (ASCT) is of great clinical significance.
  • RESULTS: Sixteen of 31 patients (52%) progressed/relapsed or died after a median follow-up of 7 months, the remaining 15 patients (48%) were disease free after a median follow-up of 24 months.
  • [MeSH-major] Lymphoma, Non-Hodgkin / surgery. Peripheral Blood Stem Cell Transplantation. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Carmustine / administration & dosage. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Melphalan / administration & dosage. Middle Aged. Predictive Value of Tests. Prednisolone / administration & dosage. Prednisone / administration & dosage. Proportional Hazards Models. Radiopharmaceuticals. Rituximab. Teniposide / administration & dosage. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132658.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Radiopharmaceuticals; 04079A1RDZ / Cytarabine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 957E6438QA / Teniposide; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone; BEAM regimen; Dexa-BEAM protocol; VAP-cyclo protocol
  •  go-up   go-down


8. Radić-Kristo D, Planinc-Peraica A, Ostojić S, Vrhovac R, Kardum-Skelin I, Jaksić B: Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics. Coll Antropol; 2010 Jun;34(2):413-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics.
  • Primary non-Hodgkin lymphomas of gastrointestinal tract (PGI-NHL) are the most common extranodal lymphomas with an increasing incidence.
  • According to World Health Organization (WHO) classification, 29 (87%) patients had diffuse large B-cell lymphoma (DLCBL), two had mantle cell lymphoma, and seven (18%) had marginal zone B-cell lymphoma-mucosa associated tissue (MALT).
  • Four (10%) patients had progressive disease.
  • In our patients, the major prognostic factor for outcome was the stage of disease.
  • Patients with localized lymphoma (stage IE and IIE) had a significantly longer overall survival: 85% at five years and 65% at ten years.
  • Patients with extended disease (stage IIIE and IVE) had overall survival less than 33%.
  • Disease stage and LDH were the only parameters that had a statistically significant effect patient survival.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Colonic Neoplasms / epidemiology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Female. Humans. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / mortality. Intestinal Neoplasms / pathology. Male. Middle Aged. Neoplasm Staging. Rectal Neoplasms / epidemiology. Rectal Neoplasms / mortality. Rectal Neoplasms / pathology. Retrospective Studies. Sigmoid Neoplasms / epidemiology. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Survival Rate. Young Adult


9. Chim CS, Shek TW: Primary gastrointestinal lymphoma of the colon. Haematologica; 2005 Nov;90 Suppl:EIM01
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal lymphoma of the colon.
  • [MeSH-major] Colonic Neoplasms / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Colonoscopy. Gastrointestinal Hemorrhage / etiology. Humans. Male. Rectum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266930.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Gayed I, Eskandari MF, McLaughlin P, Pro B, Diba R, Esmaeli B: Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging; 2007 Jul-Aug;38(4):319-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The clinical records of 16 consecutive patients with ocular adnexal lymphoma for whom pretreatment and posttreatment PET scans and corresponding computed tomography (CT) and magnetic resonance imaging (MRI) scans were available were compared.
  • In 1 patient with low-grade follicular lymphoma of the orbit, PET revealed an additional focus of lymphoma in the deltoid muscle that was missed on clinical examination and conventional radiography.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Orbital Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674923.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


11. Tran L, Baars JW, Aarden L, Beijnen JH, Huitema AD: Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Hum Antibodies; 2010;19(1):7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In this study, we investigated the pharmacokinetics of rituximab in patients with CD20 positive non-Hodgkin lymphoma, to get more insight into the factors that influence the pharmacokinetics of rituximab.
  • Apart from one patient with mantle cell lymphoma, all patients on induction therapy had a complete response.
  • Although the patient population was small, the results support the need for more research into the pharmacokinetics and factors that might influence the pharmacokinetic-pharmacodynamic relationships of rituximab in patients with non-Hodgkin lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Antigens, CD20 / metabolism. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies / blood. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Carmustine. Cyclophosphamide / administration & dosage. Doxorubicin. Drug Administration Schedule. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Prednisone. Rituximab. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine. Vindesine

  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20555126.001).
  • [ISSN] 1875-869X
  • [Journal-full-title] Human antibodies
  • [ISO-abbreviation] Hum Antibodies
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; RSA8KO39WH / Vindesine; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone; CHOP protocol; COP protocol 2; PECC protocol
  •  go-up   go-down


12. Kułakowska A, Pogorzelski R, Drozdowski W: [Primary central nervous system lymphoma with initial symptoms suggesting herpes encephalitis]. Pol Merkur Lekarski; 2008 Jan;24(139):30-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary central nervous system lymphoma with initial symptoms suggesting herpes encephalitis].
  • Primary central nervous system lymphoma (PCNSL) is rare neoplasm, affecting both immunocompetent and immunodeficient patients.
  • [MeSH-major] Brain Neoplasms / diagnosis. Encephalitis, Herpes Simplex / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634249.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


13. Etto L, Lacerda E, Baiocchi O, Silva V, Dalboni M, Alves A, Silva M, Vettore A, Colleoni G: Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk Lymphoma; 2008 Feb;49(2):257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.
  • [MeSH-major] Cytokines / blood. Hepatocyte Growth Factor / blood. Lymphoma, Non-Hodgkin / diagnosis. Tumor Burden
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brazil. Case-Control Studies. Female. Fibroblast Growth Factors / blood. Humans. Male. Middle Aged. Prognosis. Severity of Illness Index. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231911.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Vascular Endothelial Growth Factor A; 62031-54-3 / Fibroblast Growth Factors; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


14. Morris B, Partap S, Yeom K, Gibbs IC, Fisher PG, King AA: Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report. Neurology; 2009 Dec 1;73(22):1906-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report.
  • Unfortunately, irradiation is associated with untoward effects, including stroke and other cerebrovascular disease (CVD).
  • Common manifestations of radiation-induced CVD includes steno-occlusive disease, moyamoya, aneurysm, mineralizing microangiopathy, vascular malformations, and strokelike migraines.
  • CONCLUSION: Risk for stroke is increased in survivors of pediatric CNS tumors, Hodgkin lymphoma, and acute lymphoblastic leukemia who received radiation to the brain and/or neck.
  • As the population of survivors ages, vigilance for stroke and cerebrovascular disease needs to continue based on specific exposures during curative cancer therapy.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4386-94 [14645429.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2831-7 [14657067.001]
  • [Cites] Radiology. 2004 Jan;230(1):93-9 [14645879.001]
  • [Cites] Am J Surg. 2004 May;187(5):594-8 [15135672.001]
  • [Cites] Neurol Clin. 2004 Feb;22(1):39-53 [15062527.001]
  • [Cites] Radiology. 1971 Apr;99(1):87-94 [4994135.001]
  • [Cites] J Can Assoc Radiol. 1974 Jun;25(2):94-104 [4851025.001]
  • [Cites] Neurology. 1975 Feb;25(2):189-94 [1167648.001]
  • [Cites] Cancer. 1978 Aug;42(2):717-28 [277284.001]
  • [Cites] Neurology. 1986 Sep;36(9):1173-8 [3748382.001]
  • [Cites] Arch Neurol. 1989 Apr;46(4):449-55 [2650664.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):32-5 [8315466.001]
  • [Cites] Neuroradiology. 1995 May;37(4):331-3 [7666975.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] Acta Radiol. 1997 Jan;38(1):37-42 [9059399.001]
  • [Cites] Int J Radiat Biol. 1997 Jul;72(1):45-53 [9246193.001]
  • [Cites] Neurobiol Dis. 1995 Feb;2(1):13-21 [8980005.001]
  • [Cites] Radiat Res. 1998 Apr;149(4):350-9 [9525499.001]
  • [Cites] Radiology. 1999 Aug;212(2):475-82 [10429706.001]
  • [Cites] Leukemia. 2005 Jan;19(1):13-7 [15526028.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4979-90 [15576413.001]
  • [Cites] Neurology. 2005 Feb 8;64(3):553-5 [15699396.001]
  • [Cites] Neurology. 2007 Mar 20;68(12):932-8 [17372129.001]
  • [Cites] J Neurosurg. 2007 May;106(5 Suppl):379-83 [17566205.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Jul;29(7):480-4 [17609626.001]
  • [Cites] Pediatrics. 2008 Mar;121(3):633-42 [18310216.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5119-25 [18725647.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1033-40 [19336557.001]
  • [Cites] Pediatr Neurosurg. 2009;45(2):105-13 [19307744.001]
  • [Cites] J Natl Cancer Inst. 2009 Jul 1;101(13):928-37 [19535773.001]
  • [Cites] Acta Oncol. 2005;44(1):13-22 [15848902.001]
  • [Cites] Childs Nerv Syst. 2005 May;21(5):358-64 [15696334.001]
  • [Cites] Eur J Cancer. 2005 May;41(7):1026-30 [15862751.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6508-15 [16170160.001]
  • [Cites] Radiat Res. 2005 Nov;164(5):662-8 [16238444.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1361-7 [16169673.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):718-25 [16353211.001]
  • [Cites] Neurology. 2006 Apr 11;66(7):1105-7 [16606929.001]
  • [Cites] Childs Nerv Syst. 2006 Jun;22(6):547-55 [16607532.001]
  • [Cites] J Neurosurg. 2006 Aug;105(2 Suppl):134-9 [16922075.001]
  • [Cites] Neurology. 2006 Aug 22;67(4):676-8 [16707725.001]
  • [Cites] J Vasc Surg. 2006 Sep;44(3):661-72 [16950453.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):860-6 [17011458.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5277-82 [17088567.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):268-72 [16615044.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1765-72 [17047152.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):121-7 [12672284.001]
  • [Cites] Radiology. 1999 Oct;213(1):167-72 [10540657.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):323-8 [10587192.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Apr;126(4):517-21 [10772307.001]
  • [Cites] Cancer. 2000 May 1;88(9):2116-21 [10813724.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30 [11878576.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3285-91 [12115362.001]
  • [CommentIn] Neurology. 2009 Dec 1;73(22):1816-7 [19846829.001]
  • (PMID = 19812380.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K23HL079073; United States / NCI NIH HHS / CA / U10-CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  • [Other-IDs] NLM/ PMC2788797
  •  go-up   go-down


15. Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen CC, Gau JP, Yang MH: Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome. Int J Oncol; 2008 Sep;33(3):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
  • Overexpression of DcR3 has been observed in several human malignancies; however, only limited information exists on the role of DcR3 in non-Hodgkin lymphoma especially for B-cell origin.
  • In the current study, the expression profile of DcR3 was analyzed by RT-PCR and immunohistochemistry (IHC) in a set of lymphoma cell lines including T-cell and B-cell lymphomas.
  • The result demonstrated that overexpression of DcR3 was detected in most T-cell lymphoma cells, which was consistent with previous reports.
  • Interestingly, overexpression of DcR3 was also detected both in the B-cell lymphoma cell lines and diffuse large B cell lymphoma (DLBCL) patients.
  • An in vitro study showed that neutralization of DcR3 increased the percentage of doxorubicin-mediated apoptosis in two B-cell lymphoma cell lines, which indicated the possibility of DcR3 mediated chemo-resistance in B-cell lymphomas.
  • We suggest that overexpression of DcR3 is associated with a worse prognosis in DLBCL and the possible mechanism may act through the increase of chemo-resistance of lymphoma cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Drug Resistance, Neoplasm / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Receptors, Tumor Necrosis Factor, Member 6b / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gene Expression. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695885.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


16. Osborne RF, Hamilton JS, Avitia S: Lymphoma in the Waldeyer ring: a great masquerader. Ear Nose Throat J; 2009 Jun;88(6):954-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma in the Waldeyer ring: a great masquerader.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Nasopharyngeal Neoplasms / pathology. Tonsillar Neoplasms / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Endoscopy. Etoposide / administration & dosage. Humans. Male. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517398.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


17. Ng AK, Li S, Neuberg D, Chi R, Fisher DC, Silver B, Mauch PM: A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol; 2008 Oct;19(10):1754-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of pulmonary function in Hodgkin's lymphoma patients.
  • BACKGROUND: To prospectively study changes in lung function in Hodgkin's lymphoma (HL) patients and to explore predictors for these changes over time.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467315.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


18. Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, Tzankov A: Hodgkin lymphoma in Tyrol-a population-based study. Ann Hematol; 2009 May;88(5):449-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma in Tyrol-a population-based study.
  • We aimed to analyze the epidemiology, clinical characteristics, and outcome of patients with Hodgkin lymphoma (HL) diagnosed in Tyrol.
  • Among the 158 cases included, nodular lymphocytic predominant HL (nodular paragranuloma) was identified in ten cases (6%) whereas the majority of patients had classical Hodgkin lymphoma.
  • Age (p < 0.01), sex (p = 0.03), risk groups according to the German Hodgkin Study Group stratification (p < 0.01), and bone marrow infiltration (p < 0.01) were of prognostic significance considering overall survival (OS) whereas histological subtype and bulky disease were not.
  • Furthermore, 3% of HL patients had an antecedent malignant hematological disease before occurrence of HL.
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Child. Child, Preschool. Combined Modality Therapy. Female. Hematologic Neoplasms. Humans. Infant. Male. Middle Aged. Neoplasms, Second Primary. Prognosis. Risk Factors. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846373.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Falchi L, Capello D, Palumbo B, Rauco A, Emili R, Cianciulli M, Pace R, Capparella V, Liberati F, Liberati AM: A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy. Eur J Haematol; 2007 Nov;79(5):455-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
  • We report the case of an Epstein-Barr virus (EBV)- and human immunodeficiency virus-serum negative patient suffering from repeatedly relapsing classical Hodgkin's Lymphoma (cHL) associated with a histological picture of plasma cell-hyaline vascular (PC-HV) form of Castleman's disease (CD).
  • The CD30- and CD15-positive, Reed-Sternberg/Hodgkin cells, only occasionally expressed the CD20 molecule, but not leukocyte common antigen and latent membrane protein-1.
  • Relapsing cHL in the context of mixed PC-HV CD was documented in two of three surgically excised abdominal lymph nodes never previously enlarged or involved by any lymphoproliferative disease.
  • Because of the limited disease extension and failure to induce continuous remission with previous conventional chemoradiotherapy, the patient was treated with six rituximab injections.
  • Because of uncertain persistent disease in the supraclavicular nodal site, involved-field radiotherapy (RT) was delivered in that area as consolidation treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Giant Lymph Node Hyperplasia / complications. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Hyalin / metabolism. Immunologic Factors / therapeutic use. Plasma Cells
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Chemotherapy, Adjuvant. Female. Fluorodeoxyglucose F18. Humans. Positron-Emission Tomography. Radiopharmaceuticals. Radiotherapy, Adjuvant. Recurrence. Rituximab. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Castleman's Disease.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2003 Jun 13;17(9):1409-10 [12799570.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):585-6 [15090823.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1939-41 [15223659.001]
  • [Cites] Blood. 1991 Jun 1;77(11):2413-8 [1710152.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):602-5 [8302342.001]
  • [Cites] Arch Pathol Lab Med. 1996 Jan;120(1):91-6 [8554455.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):569-71 [8652374.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] J Pathol. 1997 Sep;183(1):44-50 [9370946.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):482-5 [10086783.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):302-5 [15795923.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2627-32 [15998837.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):119-23 [16405432.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):882-8 [10843293.001]
  • [Cites] Head Neck. 2001 Feb;23(2):166-9 [11303634.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):790-1 [11577129.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3473-5 [11719390.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):1-5 [11815953.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):119-26 [11835348.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):310-4 [12872350.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2786-8 [12842986.001]
  • (PMID = 17908180.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2121125
  •  go-up   go-down


20. Akhtar SS, Haque IU, Wafa SM, El-Saka H, Saroor AM, Nadrah HM: Malignant lymphoma in Al-Qassim, Saudi Arabia, reclassified according to the WHO classification. Saudi Med J; 2009 May;30(5):677-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in Al-Qassim, Saudi Arabia, reclassified according to the WHO classification.
  • OBJECTIVE: To determine the frequency of various types of malignant lymphoma (ML) in the Al-Qassim region of Kingdom of Saudi Arabia (KSA) according to recently introduced the WHO classification.
  • RESULTS: Out of 385 cases reviewed, 251 (65.2%) had non-Hodgkin lymphoma (NHL) and 117 (30.4%) had Hodgkin lymphoma (HL).
  • B cell neoplasms were the most common NHL seen (81.6%) and diffuse large B cell lymphoma (DLBCL) was the most frequent type of NHL encountered (50.1%).
  • Indolent lymphomas like follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) were rather uncommon (13.2%).
  • T cell lymphoma comprised 18.3% of the NHL.
  • The most common type of HL was nodular sclerosis classical Hodgkin lymphoma (NSCHL) (68.3%).
  • [MeSH-major] Lymphoma / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Saudi Arabia. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417969.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


21. Lin C, Loberiza FR Jr: Low-dose radiation and secondary malignancy: is there a causal relationship? Clin Lymphoma Myeloma; 2007 Jul;7(7):450
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiography. Neoplasms, Radiation-Induced. Neoplasms, Second Primary. Tomography, X-Ray Computed / adverse effects
  • [MeSH-minor] Adult. Dose-Response Relationship, Radiation. Follow-Up Studies. Humans. Male. Neoplasm Staging / adverse effects. Risk Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Lymphoma Myeloma. 2007 Jul;7(7):467-9 [17875235.001]
  • (PMID = 17875233.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


22. Ness KK, Mertens AC, Hudson MM, Wall MM, Leisenring WM, Oeffinger KC, Sklar CA, Robison LL, Gurney JG: Limitations on physical performance and daily activities among long-term survivors of childhood cancer. Ann Intern Med; 2005 Nov 1;143(9):639-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Survivors of childhood cancer may experience important disease- and treatment-related late effects, including functional limitations.
  • PATIENTS: Participants included 11 481 persons who were treated for primary brain cancer, leukemia, Hodgkin disease, non-Hodgkin lymphoma, kidney tumor, neuroblastoma, soft-tissue sarcoma, or malignant bone tumor before the age of 21 years and who survived at least 5 years after diagnosis.
  • [MeSH-minor] Absenteeism. Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Schools. Surveys and Questionnaires. Work


23. Catellani S, Poggi A, Bruzzone A, Dadati P, Ravetti JL, Gobbi M, Zocchi MR: Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood; 2007 Mar 1;109(5):2078-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins.
  • Data on 23 patients with low-grade non-Hodgkin lymphomas (NHLs), 4 mantle (MT), 4 marginal zone (MZ), and 15 follicular (FL), were analyzed and compared with 10 high-risk (HR) B-cell chronic lymphocytic leukemias (B-CLLs) with lymph node involvement and 4 diffuse large-cell lymphomas (DLCLs).
  • Moreover, Vdelta1 T lymphocytes from patients with FL NHL proliferate in response to ULBP2+ and ULBP3+ lymphoma cells.
  • Finally, patients with high expression of ULBPs, increased circulating Vdelta1 T lymphocytes, and high levels of serum IL-4 showed stable disease in a 1-year follow-up in contrast to patients with low circulating Vdelta1 T cells and undetectable IL-4 or ULBPs.
  • [MeSH-major] Carrier Proteins / metabolism. Histocompatibility Antigens Class I / metabolism. Immunoglobulin delta-Chains / metabolism. Interleukin-4 / biosynthesis. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology. T-Lymphocytes / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Cells, Cultured. Disease Progression. Female. Follow-Up Studies. GPI-Linked Proteins. Humans. Intercellular Signaling Peptides and Proteins. Male. Middle Aged. Neoplasm Staging. Protein Binding. Transcription, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16973957.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / GPI-Linked Proteins; 0 / Histocompatibility Antigens Class I; 0 / Immunoglobulin delta-Chains; 0 / Intercellular Signaling Peptides and Proteins; 0 / ULBP2 protein, human; 0 / ULBP3 protein, human; 207137-56-2 / Interleukin-4
  •  go-up   go-down


24. Gualco G, Bacchi CE: B-cell and T-cell lymphomas of the breast: clinical--pathological features of 53 cases. Int J Surg Pathol; 2008 Oct;16(4):407-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast involvement by non-Hodgkin lymphomas is rare.
  • Four of the patients with primary breast lymphomas had T-cell lymphomas, 3 had CD30-positive anaplastic large cell lymphomas, and 1 had panniculitis-like T-cell lymphoma.
  • Secondary breast lymphoma was seen in 19 patients and most commonly occurred as part of widespread nodal disease.
  • The most prevalent histological subtype was also diffuse large B-cell lymphoma, followed by follicular lymphoma.
  • This study shows that the broad morphological and immunophenotypical spectrum of malignant lymphoma of the breast occurring in a large series of Brazilian patients has many similarities with that seen in Western countries, with a higher proportion of high-grade lymphomas in both primary and secondary cases.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms, Male / pathology. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480397.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 070058; United States / NCI NIH HHS / CA / CA082274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


25. Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, Dörffel W: Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma. J Clin Oncol; 2005 Jun 20;23(18):4048-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma.
  • PURPOSE: The prognostic significance of latent Epstein-Barr virus (EBV) infection in Hodgkin's lymphoma (HL) is debated controversially.
  • PATIENTS AND METHODS: Eight hundred forty-two children and adolescents (median age, 13.7 years) from pediatric multicenter treatment studies HD-90 and HD-95 were studied for latent EBV infection in Hodgkin's and Reed-Sternberg cells by immunostaining against latent membrane protein 1 (LMP-1).
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology. Viral Matrix Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Prognosis. Proportional Hazards Models. Reed-Sternberg Cells / virology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15961758.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


26. Bosler DS, Douglas-Nikitin VK, Harris VN, Smith MD: Detection of T-regulatory cells has a potential role in the diagnosis of classical Hodgkin lymphoma. Cytometry B Clin Cytom; 2008 Jul;74(4):227-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of T-regulatory cells has a potential role in the diagnosis of classical Hodgkin lymphoma.
  • Previous studies have demonstrated an increase in T-regulatory cells in the involved lymph nodes and peripheral blood of patients with Hodgkin lymphoma.
  • Our study examined whether the detection of T-regulatory cells by flow cytometry could distinguish classical Hodgkin lymphoma (CHL) from benign cases and B-cell non-Hodgkin lymphomas (B-NHL).
  • We measured CD4, CD25, and CD152 in 14 CHLs, 2 nodular lymphocyte-predominant Hodgkin lymphomas, 31 B-NHLs, and 54 benign cases.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adult. Aged. Animals. Antigens, CD / immunology. CD4-CD8 Ratio. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. CTLA-4 Antigen. Female. Flow Cytometry. Granulomatous Disease, Chronic / immunology. Humans. Interleukin-2 Receptor alpha Subunit / immunology. Lymph Nodes / cytology. Lymph Nodes / immunology. Male. Middle Aged. ROC Curve. T-Lymphocyte Subsets / immunology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Clinical Cytometry Society
  • (PMID = 18271019.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


27. Levitt MJ, Gharibo M, Strair R, Schaar D, Rubin A, Bertino JR: Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate. J Chemother; 2009 Aug;21(4):434-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pilot study tested the hypothesis that dose intensity/dose density treatment may improve the response rate and remission duration in patients with advanced low grade lymphomas. ten patients with low grade lymphomas: follicular lymphoma grades I and II, marginal zone lymphoma, and small cell lymphocytic lymphoma with progressive disease were studied.
  • Patients had an ECOG performance of 0-2, and Stage III and IV disease.
  • Both untreated and previously treated patients with progressive disease were eligible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622463.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 5-P30-CA 072720-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


28. Wedrychowicz A, Spodaryk M, Krasowska-Kwiecień A, Goździk J: Total parenteral nutrition in children and adolescents treated with high-dose chemotherapy followed by autologous haematopoietic transplants. Br J Nutr; 2010 Mar;103(6):899-906
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Calcium / administration & dosage. Child. Child, Preschool. Endodermal Sinus Tumor / therapy. Female. Hodgkin Disease / therapy. Humans. Infant. Magnesium / administration & dosage. Male. Neuroblastoma / therapy. Nutritional Status. Potassium / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Sarcoma, Ewing / therapy. Transplantation, Autologous. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860986.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] I38ZP9992A / Magnesium; RWP5GA015D / Potassium; SY7Q814VUP / Calcium
  •  go-up   go-down


29. Dörr W, Köst S, Keinert K, Glaser FH, Endert G, Herrmann T: Early intestinal changes following abdominal radiotherapy comparison of endpoints. Strahlenther Onkol; 2006 Jan;182(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Abdomen / radiation effects. Adolescent. Adult. Aged. Dose Fractionation. Dose-Response Relationship, Radiation. Female. Hodgkin Disease / radiotherapy. Humans. Intestinal Absorption / radiation effects. Kidney Neoplasms / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Middle Aged. Prospective Studies. Radiotherapy Dosage. Rhabdomyosarcoma / radiotherapy. Seminoma / radiotherapy. Stomach Neoplasms / radiotherapy. Testicular Neoplasms / radiotherapy. Time Factors. Vitamin B 12 / pharmacokinetics. Xylose / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404514.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] A1TA934AKO / Xylose; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


30. Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D: Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood; 2005 Nov 1;106(9):3166-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.
  • We previously observed a loss of Epstein-Barr virus (EBV)-specific CD8+ T cells in subjects progressing to EBV-related non-Hodgkin lymphoma (NHL), correlating with loss of CD4+ T cells.
  • However, whereas latent antigen EBNA1-specific CD4+ T cells were lost well before diagnosis in all subjects who developed an AIDS-related NHL (and EBNA1-specific CD8+ T cells were significantly lower compared with the other groups), these cells were better preserved in progressors to non-EBV-related disease and slow progressors.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Epstein-Barr Virus Nuclear Antigens / immunology. Immunologic Memory / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / immunology. Acquired Immunodeficiency Syndrome / virology. Adult. Cell Proliferation. Disease Progression. HIV-1 / immunology. HIV-1 / physiology. Humans. Kinetics. Middle Aged


31. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol; 2009 Aug 10;27(23):3822-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
  • PURPOSE: Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL).
  • We evaluated two dose regimens of temsirolimus in comparison with investigator's choice single-agent therapy in relapsed or refractory disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / drug effects. Sirolimus / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Kaplan-Meier Estimate. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Recurrence. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581539.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 624KN6GM2T / temsirolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


32. Spinelli JJ, Ng CH, Weber JP, Connors JM, Gascoyne RD, Lai AS, Brooks-Wilson AR, Le ND, Berry BR, Gallagher RP: Organochlorines and risk of non-Hodgkin lymphoma. Int J Cancer; 2007 Dec 15;121(12):2767-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organochlorines and risk of non-Hodgkin lymphoma.
  • Organochlorine chemicals and polychlorinated biphenyls (PCBs) have been suspected as possible risk factors for non-Hodgkin lymphoma (NHL).
  • [MeSH-major] Environmental Exposure / adverse effects. Environmental Pollutants / blood. Lymphoma, Non-Hodgkin / chemically induced. Lymphoma, Non-Hodgkin / epidemiology. Pesticides / blood. Polychlorinated Biphenyls / blood
  • [MeSH-minor] Adult. Aged. British Columbia / epidemiology. Case-Control Studies. Chlordan / analogs & derivatives. Chlordan / blood. Female. Humans. Hydrocarbons, Chlorinated / blood. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Registries. Risk Assessment. Risk Factors. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYCHLORDANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17722095.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated; 0 / Pesticides; 12789-03-6 / Chlordan; 27304-13-8 / oxychlordane; DFC2HB4I0K / Polychlorinated Biphenyls
  •  go-up   go-down


33. Figl A, Thirumaran RK, Ugurel S, Gast A, Hemminki K, Kumar R, Schadendorf D: Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. Arch Dermatol; 2007 Apr;143(4):495-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
  • OBSERVATIONS: We describe a 25-year-old German woman who developed 8 invasive melanomas and 6 in situ melanomas after radiation therapy and polychemotherapy for Hodgkin lymphoma.
  • Analysis of DNA from paraffin-embedded tissues showed loss of heterozygosity at CDKN2A loci in all 3 melanomas studied but not in Hodgkin lymphoma.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Genetic Predisposition to Disease. Germ-Line Mutation. Hodgkin Disease / therapy. Melanoma / genetics. Neoplasms, Multiple Primary / genetics. Receptor, Melanocortin, Type 1 / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Female. Genes, p16. Humans. Loss of Heterozygosity. Pedigree. Penetrance


34. Simon Z, Keresztes K, Miltényi Z, Ress Z, Váróczy L, Vadász G, Gergely L, Illés A: [Our experiences in treating patients with Hodgkin disease in the last decade]. Orv Hetil; 2007 Apr 15;148(15):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Our experiences in treating patients with Hodgkin disease in the last decade].
  • [Transliterated title] Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben.
  • INTRODUCTION: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred.
  • AIM: To summarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004.
  • RESULTS: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%).
  • During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons.
  • CONCLUSION: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hungary. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416575.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol; MOPP protocol
  •  go-up   go-down


35. Duarte C, Couto M, Inês L, Silva J, Sousa I, Malcata A: [Difuse non-Hodgkin lymphoma in a patient with systemic lupus erythematosus]. Acta Reumatol Port; 2009 Jan-Mar;34(1):106-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Difuse non-Hodgkin lymphoma in a patient with systemic lupus erythematosus].
  • [Transliterated title] Linfoma difuso de grandes células em doente com Lúpus Eritematoso Sistémico.
  • She presented with constitutional symptoms and back pain and one month later a diagnosis of Non Hodgkin Lymphoma was established (subtype Diffuse Large B Cells Lymphoma).
  • [MeSH-major] Lupus Erythematosus, Systemic / complications. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Adult. Female. Humans. Risk Factors


36. Mathew P, Elting L, Cooksley C, Owen S, Lin J: Cancer in an incarcerated population. Cancer; 2005 Nov 15;104(10):2197-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disease sites and associated mortality of the inmate cancer patients were determined and compared with SEER cohorts.
  • The leading cancers were lung carcinoma, non-Hodgkin lymphoma (NHL), and carcinomas of the oral cavity and pharynx.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Continental Population Groups. Female. Humans. Male. Middle Aged. Prevalence. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16206295.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A: IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant; 2007 Dec;40(11):1019-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.
  • We explored the efficacy of the IGEV regimen (ifosfamide, gemcitabine, vinorelbine and prednisone) combined with a fixed dose of lenograstim (263 mug/day) to mobilize peripheral blood stem cells (PBSCs) in 90 Hodgkin's lymphoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colony-Stimulating Factors / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Hodgkin Disease / therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Graft Survival. Humans. Ifosfamide / administration & dosage. Middle Aged. Recombinant Proteins / therapeutic use. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906705.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Colony-Stimulating Factors; 0 / Recombinant Proteins; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5V9KLZ54CY / Vinblastine; 6WS4C399GB / lenograstim; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


38. Hasserjian RP, Chen S, Perkins SL, de Leval L, Kinney MC, Barry TS, Said J, Lim MS, Finn WG, Medeiros LJ, Harris NL, O'Malley DP: Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol; 2009 Dec;22(12):1532-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included 6 cases of B-cell lymphoma, 2 cases of T-cell lymphoma, 3 cases of classical Hodgkin lymphoma, and 7 atypical lymphoid proliferations that did not fulfill diagnostic criteria for lymphoma; two of the latter regressed after discontinuation of the immunomodulator agent therapy.
  • All eight lymphoma patients with available information had also received prior chemotherapy (methotrexate or 6-mercaptopurine).
  • EBV was strongly associated with the B-cell and classical Hodgkin lymphomas.
  • [MeSH-major] Autoimmune Diseases / drug therapy. Iatrogenic Disease. Immunologic Factors / adverse effects. Lymphoproliferative Disorders / chemically induced
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Belgium. Female. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / chemically induced. Humans. Immunosuppressive Agents / adverse effects. Lymphoma, B-Cell / chemically induced. Lymphoma, T-Cell / chemically induced. Male. Middle Aged. Treatment Outcome. United States. Young Adult

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767727.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Immunosuppressive Agents
  •  go-up   go-down


39. Kalaycio M, Pohlman B, Kuczkowski E, Rybicki L, Andresen S, Sobecks R, Bolwell B: High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant. Clin Transplant; 2006 Nov-Dec;20(6):783-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The non-relapse mortality of autologous stem cell transplant is low enough that the procedure has been extended to older patients with non-Hodgkin's lymphoma.
  • We treated 537 non-Hodgkin's lymphoma patients with high-dose chemotherapy consisting of busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplant.
  • [MeSH-major] Busulfan / administration & dosage. Immunosuppressive Agents / administration & dosage. Lung Diseases / mortality. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100730.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; G1LN9045DK / Busulfan
  •  go-up   go-down


40. Martín-Subero JI, Klapper W, Sotnikova A, Callet-Bauchu E, Harder L, Bastard C, Schmitz R, Grohmann S, Höppner J, Riemke J, Barth TF, Berger F, Bernd HW, Claviez A, Gesk S, Frank GA, Kaplanskaya IB, Möller P, Parwaresch RM, Rüdiger T, Stein H, Küppers R, Hansmann ML, Siebert R, Deutsche Krebshilfe Network Project Molecular Mechanisms in Malignant Lymphomas: Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res; 2006 Nov 1;66(21):10332-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.
  • However, despite the predominant B-cell origin of the Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL), the presence of chromosomal translocations in IG loci has not yet been systematically explored.
  • [MeSH-major] Chromosome Breakage. Genes, Immunoglobulin Heavy Chain. Hodgkin Disease / genetics. Reed-Sternberg Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Caspases / genetics. DNA-Binding Proteins / genetics. Female. Genes, myc. Humans. Immunoglobulin Class Switching. Immunoglobulin Constant Regions / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Proteins / genetics. Recurrence. Translocation, Genetic

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17079453.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Constant Regions; 0 / Neoplasm Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


41. Chamberlain MC, Tsao-Wei DD, Groshen S: Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer; 2006 May 1;106(9):2021-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor histologies included lung (8 patients), breast (5 patients), primary brain tumor (4 patients), non-Hodgkin lymphoma (4 patients), melanoma (4 patients), colon (1 patient), and prostate (1 patient).
  • Eight patients (30%) developed disease progression during induction therapy and did not complete the 8-week induction course of therapy.
  • In responding patients, time to neurologic disease progression ranged from 8 weeks to 40 weeks (median, 20 wks).
  • The 6-month neurologic disease progression-free survival was 11%.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Meningitis.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583432.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


42. Sahni CS, Desai SB: Distribution and clinicopathologic characteristics of non-Hodgkin's lymphoma in India: a study of 935 cases using WHO classification of lymphoid neoplasms (2000). Leuk Lymphoma; 2007 Jan;48(1):122-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and clinicopathologic characteristics of non-Hodgkin's lymphoma in India: a study of 935 cases using WHO classification of lymphoid neoplasms (2000).
  • The frequency of various subtypes of non-Hodgkin's lymphoma (NHL) differs in various regions worldwide.
  • Diffuse large B-cell lymphoma (DLBL) was the most common subtype (50.2%).
  • A lower frequency of follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma (MCL) was noted compared to that observed in the developed countries, whereas a lower frequency of peripheral T-cell lymphoma - not otherwise specified (PTCL-NOS) and extranodal NK/T-cell lymphoma was seen compared to that in the other Asian countries.
  • A higher frequency of DLBL and precursor T-lymphoblastic leukemia/lymphoma was noted.
  • Null/T-cell anaplastic large cell lymphoma presented in the older age.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. World Health Organization
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. India / epidemiology. Leukemia, Lymphoid / classification. Leukemia, Lymphoid / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325856.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Aleknavicius E, Valuckas KP, Aleknaviciene B, Norkiene L, Smailyte G: [Treatment results of Hodgkin's lymphoma]. Medicina (Kaunas); 2009;45(8):615-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results of Hodgkin's lymphoma].
  • During last decades, there are strengthening attitudes to optimize the treatment of Hodgkin's lymphoma considering prognostic groups and risk factors.
  • In 83% of cases, classic nodular sclerotic Hodgkin's lymphoma was diagnosed.
  • Advanced-, intermediate-, and early-stage disease was diagnosed in 55%, 38%, and 7% of cases, respectively.
  • The patients with early-stage disease underwent four ABVD chemotherapy courses; 88% of them underwent radiotherapy afterwards.
  • The patients with intermediate-stage disease underwent 4-6 courses of ABVD or in minor cases (12% of patients with intermediate-stage disease) - 4 standard BEACOPP chemotherapy courses.
  • After this treatment, 88% of patients with intermediate-stage disease underwent radiotherapy.
  • Patients with advanced-stage disease underwent 8 escalate (44%) or standard BEACOPP (29%) chemotherapy courses.
  • Overall survival and event-free survival in patients with early-stage disease was 100%.
  • Overall survival in patients with early/intermediate- and advanced-stage disease was 95.1% and 84.0%, respectively.
  • Event-free survival in patients with early/intermediate- and advanced-stage disease was 91.7% and 76.2%, respectively.
  • In the groups of intermediate- and advanced-stage disease, the results of treatment were worse in the subgroup, which underwent extended-field radiotherapy (P<0.05).
  • Overall survival in the group of patients with advanced-stage disease was the best who underwent ABVD scheme, but the event-free survival (70.6%) and disease-free survival (81.3%) in ABVD subgroup were worse compared to BEACOPP subgroup.
  • According to our results, there was no statistically significant difference in survival of patients with advanced-stage disease who underwent or did not radiotherapy (P>0.05).
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Data Interpretation, Statistical. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773620.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


44. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood; 2006 Jan 1;107(1):52-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.
  • Risk-adapted lymphoma treatment requires early and accurate assessment of prognosis.
  • This investigation prospectively assessed the value of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS) in Hodgkin lymphoma (HL).
  • Other significant prognostic factors were stage and extranodal disease.
  • A positive early interim FDG-PET is highly predictive of progression in patients with advanced-stage or extranodal disease.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Positron-Emission Tomography / methods. Predictive Value of Tests
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Regression Analysis. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150944.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


45. Novelli G, Rossi M, Ferretti G, Nudo F, Bussotti A, Mennini G, Novelli L, Ferretti S, Antonellis F, Martelli S, Berloco PB: Molecular adsorbent recirculating system treatment for acute hepatic failure in patients with hepatitis B undergoing chemotherapy for non-Hodgkin's lymphoma. Transplant Proc; 2005 Jul-Aug;37(6):2560-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular adsorbent recirculating system treatment for acute hepatic failure in patients with hepatitis B undergoing chemotherapy for non-Hodgkin's lymphoma.
  • We used the Molecular Adsorbent Recirculating System (MARS) (MARS Monitor; Teraklin AG, Rostock, Germany) to treat 5 HBsAg-positive lymphoma patients with acute hepatic failure due to chemotherapy despite lamivudine treatment.
  • [MeSH-major] Hepatitis B / complications. Liver Failure, Acute / therapy. Lymphoma, Non-Hodgkin / complications. Sorption Detoxification / methods
  • [MeSH-minor] Adult. Brain / radiography. Electroencephalography. Hemodynamics. Hepatitis B Surface Antigens / blood. Hepatitis B e Antigens / blood. Humans. Liver Function Tests. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182743.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B e Antigens
  •  go-up   go-down


46. Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, Hartmann E, Rudiger T, Jaffe ES, Müller-Hermelink HK, Ott G, Fend F, Rosenwald A: IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol; 2007 Oct;31(10):1605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
  • Approximately 5% of B-cell chronic lymphocytic leukemia (B-CLL) patients develop a secondary aggressive lymphoma, usually of diffuse large B-cell type (DLBCL), termed Richter's transformation (RT).
  • Rarely, classic Hodgkin lymphoma (HL) is observed.
  • Published small series suggest that tumor cells in DLBCL and HL can be clonally identical to the B-CLL clone or arise as an independent, secondary lymphoma.
  • We describe the morphology, immunophenotype, and clinical features of 34 classic RT patients with DLBCL, 6 cases of B-CLL with HL, and 8 cases with scattered CD30-positive Hodgkin and Reed-Sternberg (HRS)-like cells.
  • In classic RT, 18/23 B-CLL cases (78%) showed clonal progression to DLBCL with identical IgVH sequences in both lymphoma components, whereas in 5 cases (22%) the DLBCL was clonally unrelated.
  • [MeSH-major] Hodgkin Disease / genetics. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Clone Cells. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Gene Rearrangement, B-Lymphocyte. Humans. Lasers. Male. Microdissection. Middle Aged. Polymerase Chain Reaction. Somatic Hypermutation, Immunoglobulin


47. Ohga S, Nakamura K, Shioyama Y, Sasaki T, Urashima Y, Terashima H, Honda H: Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy. Radiat Med; 2005 May;23(3):156-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy.
  • PURPOSE: We evaluated the usefulness of radiotherapy plus THP-COP chemotherapy consisting of cyclophosphamide, vincristine, pirarubicin (tetrahydropyranyl adriamycin, THP), and prednisone for stage I and II non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940061.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


48. Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, Sudeck H, Schmidt-Wolf IG, Anagnostopoulos I, Huhn D: Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial. Cancer; 2006 Apr 1;106(7):1560-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
  • BACKGROUND: Highly active antiretroviral therapy (HAART) has improved the survival of patients with acquired immunodeficiency syndrome-related lymphoma (ARL).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Administration, Oral. Adult. Age Factors. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Infusions, Intravenous. Male. Prednisone / administration & dosage. Prospective Studies. Risk Factors. Survival Analysis. Vincristine / administration & dosage


49. Piccirillo N, De Matteis S, De Vita S, Laurenti L, Chiusolo P, Sorà F, Reddiconto G, d'Onofrio G, Leone G, Sica S: Kinetics of peg-filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant; 2007 Sep;40(6):579-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / pharmacokinetics. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Peripheral Blood Stem Cell Transplantation. Polyethylene Glycols / pharmacokinetics
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Filgrastim. Humans. Lymphocyte Count. Male. Middle Aged. Neutrophils / cytology. Platelet Count. Recombinant Proteins. Recovery of Function / immunology. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637690.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 30IQX730WE / Polyethylene Glycols; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


50. Decaux O, Avet-Loiseau H, Grosbois B: [Malignant transformation of monoclonal gammopathy of undetermined significance]. Presse Med; 2007 Dec;36(12 Pt 3):1985-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Transformation maligne des gammapathies monoclonales de signification indéterminée.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Bone Marrow / pathology. Cell Transformation, Neoplastic. Cohort Studies. Diagnosis, Differential. Female. Follow-Up Studies. Genetic Markers. Humans. Immunoglobulin A / immunology. Immunoglobulin G / immunology. Immunoglobulin Isotypes. Immunoglobulin M / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / etiology. Multiple Myeloma / immunology. Multiple Myeloma / pathology. Myelography. Plasma Cells. Predictive Value of Tests. Retrospective Studies. Risk Factors. Time Factors. Waldenstrom Macroglobulinemia / diagnosis. Waldenstrom Macroglobulinemia / immunology. Waldenstrom Macroglobulinemia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509811.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin Isotypes; 0 / Immunoglobulin M
  • [Number-of-references] 61
  •  go-up   go-down


51. Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T, Hattori K, Matsumoto M, Inoue H, Yabe H, Yabe M, Shinohara O, Kato S: Gonadal shielding to irradiation is effective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescence. Bone Marrow Transplant; 2007 Apr;39(8):483-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An increasing number of long-term surviving bone marrow transplantation (BMT) recipients have recovered from their primary disease but are at risk of developing failure of endocrine organs.
  • [MeSH-minor] Adolescent. Adult. Anemia, Aplastic / therapy. Biopsy. Child. Follicle Stimulating Hormone / blood. Humans. Leukemia / therapy. Leydig Cells / pathology. Luteinizing Hormone / blood. Lymphoma, Non-Hodgkin / therapy. Male. Puberty. Survivors. Testicular Diseases / etiology. Testosterone / blood. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334386.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


52. Slager SL, Kay NE: Familial chronic lymphocytic leukemia: what does it mean to me? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S194-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though B-chronic lymphocytic leukemia (CLL) is known to be a heterogeneous disease, only recently has the familial component of CLL been more thoroughly investigated.
  • This entity is seen in approximately 5%-10% of all patients with CLL and can be associated with earlier age of diagnosis, higher female prevalence, and increased incidence of other lymphoproliferative disorders (LPDs), such as non-Hodgkin lymphoma and the more recently described monoclonal B-cell lymphocytosis CLL in family members.
  • The prognostic parameters and clinical course of familial CLL is not clearly distinguishable from that of sporadic disease.
  • In addition, it is not clear that the treatment responses for progressive disease has any discernible difference in familial versus sporadic CLL.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for familial chronic lymphocytic leukemia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2001 May;113(2):407-14 [11380406.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):3959-63 [19620484.001]
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Leuk Res. 2002 Sep;26(9):791-4 [12127552.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1100-1 [12150154.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2289-90 [12239136.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):866-73 [12786797.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):859-66 [12802926.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1202-10 [14576043.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]
  • [Cites] Am J Hum Genet. 1999 Jul;65(1):265-9 [10364544.001]
  • [Cites] Am J Hum Genet. 2005 Sep;77(3):420-9 [16080117.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1117-20 [16885053.001]
  • [Cites] Blood. 2007 Feb 1;109(3):916-25 [17047154.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3326-33 [17687107.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):724-9 [18021087.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):762-71 [18021089.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5691-3 [18424666.001]
  • [Cites] Cytometry B Clin Cytom. 2008 Jul;74(4):221-6 [18431797.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1204-10 [18758461.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):361-8 [18729853.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):99-108 [11699227.001]
  • (PMID = 19778840.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA118444-01; United States / NCI NIH HHS / CA / U01 CA118444; United States / NCI NIH HHS / CA / CA 118444; United States / NCI NIH HHS / CA / U01 CA118444-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  • [Other-IDs] NLM/ NIHMS277730; NLM/ PMC3061547
  •  go-up   go-down


53. Besson H, Brennan P, Becker N, De Sanjosé S, Nieters A, Font R, Maynadié M, Foretova L, Cocco PL, Staines A, Vornanen M, Boffetta P: Tobacco smoking, alcohol drinking and Hodgkin's lymphoma: a European multi-centre case-control study (EPILYMPH). Br J Cancer; 2006 Aug 7;95(3):378-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco smoking, alcohol drinking and Hodgkin's lymphoma: a European multi-centre case-control study (EPILYMPH).
  • We analysed the effects of tobacco and alcohol in the aetiology of Hodgkin's lymphoma (HL), based on 340 cases and 2465 controls enrolled in Spain, France, Italy, Germany, Ireland and Czech Republic, between 1998 and 2004.
  • [MeSH-major] Alcohol Drinking / epidemiology. Hodgkin Disease / epidemiology. Smoking / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Europe / epidemiology. Female. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Med Assoc. 1958 March 15;166(11):1294-308 [12308037.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):422-30 [16080191.001]
  • [Cites] Am J Epidemiol. 2002 Dec 1;156(11):1011-20 [12446257.001]
  • [Cites] Neuroscience. 2003;120(4):941-50 [12927200.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):305-15 [14970279.001]
  • [Cites] Eur J Cancer Prev. 2004 Apr;13(2):143-4 [15100582.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):387-97 [15141139.001]
  • [Cites] Hematol Oncol. 2004 Mar;22(1):11-26 [15152367.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1437-41 [4762928.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):297-310 [11301346.001]
  • [Cites] Blood. 2001 May 1;97(9):2798-807 [11313274.001]
  • [Cites] Cancer Causes Control. 2001 May;12(4):325-34 [11456228.001]
  • [Cites] J Natl Cancer Inst. 1977 Mar;58(3):525-47 [557114.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1489-91 [857036.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):307-14 [277717.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2571-9 [6498749.001]
  • [Cites] Br J Cancer. 1987 Jan;55(1):85-90 [3814482.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):190-3 [7829214.001]
  • [Cites] Int J Epidemiol. 1995 Jun;24(3):504-14 [7672889.001]
  • [Cites] Nutr Cancer. 1997;27(3):256-60 [9101555.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):49-56 [9486463.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):60-9 [10361588.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):6376-83 [15528377.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Mar;37(3):511-7 [15618006.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:23-9 [12078898.001]
  • (PMID = 16819547.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360649
  •  go-up   go-down


54. Rehm A, Anagnostopoulos I, Gerlach K, Broemer M, Scheidereit C, Jöhrens K, Hübler M, Hetzer R, Stein H, Lipp M, Dörken B, Höpken UE: Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma. Int J Cancer; 2009 Nov 15;125(10):2367-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma.
  • Mediastinal large B-cell lymphomas (MLBCLs) are considered as a subtype of diffuse large B-cell lymphoma; however, they exhibit completely different patterns of dissemination.
  • MLBCLs exhibit a diagnostic chemokine receptor profile that is instrumental in the discrimination from diffuse large B-cell lymphoma not otherwise specified and classical Hodgkin lymphoma.
  • Furthermore, we suggest that low-abundance expression of CCR7 and CXCR5 may hinder lymphoma cells from nodal dissemination.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Mediastinal Neoplasms / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR5 / metabolism
  • [MeSH-minor] Adolescent. B-Lymphocytes / metabolism. Cell Movement. Cells, Cultured. Chemotaxis. Child. Child, Preschool. Electrophoretic Mobility Shift Assay. Flow Cytometry. Humans. Immunoenzyme Techniques. Infant. NF-kappa B / metabolism. Thymus Gland / cytology. Thymus Gland / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536742.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR7 protein, human; 0 / CXCR5 protein, human; 0 / NF-kappa B; 0 / Receptors, CCR7; 0 / Receptors, CXCR5
  •  go-up   go-down


55. Tan WY, Hu DS, Zeng FY, Song QB, Hu S, Wei L, Zhou LQ: [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases]. Ai Zheng; 2007 Dec;26(12):1360-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
  • BACKGROUND & OBJECTIVE: The treatment strategies of Hodgkin's lymphoma (HL) are different according to clinical stage and risk factors, yet the optimal treatment strategy remains unclear.
  • The 5-and 10-year overall survival (OS) rates were 87.7% and 76.3%; the 5-and 10-year disease-free survival (DFS) rates were 79.4% and 74.5%.
  • The occurrence rate of secondary malignancies was 5.2%, including 2 cases of non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Mechlorethamine / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Prednisone / therapeutic use. Procarbazine / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076802.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; MOPP protocol
  •  go-up   go-down


56. Tavernier E, Le QH, de Botton S, Dhédin N, Bulabois CE, Reman O, Vey N, Lhéritier V, Dombret H, Thomas X: Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials. Cancer; 2007 Dec 15;110(12):2747-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials.
  • Although treatment intensity and outcome were not comparable, with improvements in survival it is important to evaluate the rate and the type of second neoplasms in adults with ALL.
  • RESULTS: By February 2005 secondary or concomitant neoplasms were documented in 23 patients, including 9 acute myeloid leukemias (AML) or myelodysplasias (MDS), 4 non-Hodgkin lymphomas (NHL), 5 skin tumors, and 5 other solid tumors (1 lung cancer, 1 tongue carcinoma, 1 thymoma, 1 condrosarcoma, 1 histiocytosis).
  • CONCLUSIONS: The data document that adult ALL survivors are at an increased risk of later malignancy.
  • Considering the low survival rate of this large unselected adult ALL cohort (32% at 10 years) as compared with that observed in childhood ALL, the risk of second malignancy remains underestimated.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Clinical Trials as Topic. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis


57. Gurol Y, Kipritci Z, Selcuk NA, Koc Y, Kocagoz S: Bacillus circulans paracardiac infection in non-hodgkin lymphoma--a case report. Prague Med Rep; 2008;109(1):19-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacillus circulans paracardiac infection in non-hodgkin lymphoma--a case report.
  • A case report is presented concerning Bacillus circulans paracardiac infection in a 27 year old woman with non-hodgkin lymphoma.
  • [MeSH-major] Bacillaceae Infections / diagnosis. Immunocompromised Host. Lymphoma, Non-Hodgkin / microbiology. Mediastinal Diseases / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097386.001).
  • [ISSN] 1214-6994
  • [Journal-full-title] Prague medical report
  • [ISO-abbreviation] Prague Med Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


58. Koutros S, Holford TR, Hahn T, Lantos PM, McCarthy PL Jr, Risch HA, Swede H: Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA. Leuk Lymphoma; 2007 Feb;48(2):357-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA.
  • Moderately increased incidence rates have been observed during the spring for leukemias and Hodgkin's disease but few studies have been conducted of non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Seasons
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Incidence. Male. Middle Aged. Registries. Risk Factors. SEER Program. Time Factors. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Feb;48(2):223-4 [17325879.001]
  • (PMID = 17325897.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67005; United States / NCI NIH HHS / CA / R25 CA47883
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


59. Segura-Ortí E: [Exercise in haemodyalisis patients: a literature systematic review]. Nefrologia; 2010;30(2):236-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ejercicio en pacientes en hemodiálisis: revisión sistemática de la literatura.
  • Exercise as a therapeutic tool used in End-stage renal disease patients (ESRD) in hemodialysis (HD) is not routinately applied, as it occurs with cardiac or respiratory patients.
  • 1) to systematically review the literature of exercise training on adult HD patients or patients at a pre-HD stage;.
  • 3) to recommend requirements of future research in order to include exercise prescription in the HD patients treatment.
  • Randomized Controlled Trials on aerobic, strength and combined programs for HD patients were selected.
  • Future studies should clarify which out of the three modalities results in higher benefits for HD patients.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Exercise. Exercise Tolerance. Female. Humans. Male. Middle Aged. Oxygen Consumption. Quality of Life. Randomized Controlled Trials as Topic / statistics & numerical data. Research Design. Resistance Training. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098466.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Number-of-references] 50
  •  go-up   go-down


60. Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S: 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging; 2005 Jul;32(7):749-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET in malignant lymphoma: significance of positive findings.
  • PURPOSE: The aim of this study was to evaluate the significance of increased uptake of 18F-fluorodeoxyglucose (FDG) in patients with malignant lymphoma (ML) studied by positron emission tomography (PET).
  • METHODS: A total of 1,120 consecutive scans carried out in 848 patients were reviewed; all patients had a diagnosis of ML [574 non-Hodgkin's lymphoma (NHL) and 274 Hodgkin's disease (HD)] and were studied at completion of therapy, for suspected recurrence or during follow-up.
  • PET findings were considered positive for lymphomatous localisation when uptake occurred at sites of previous disease, in asymmetrical lymph nodes or in nodes unlikely to be affected by inflammation (mediastinal, except for hilar, and abdominal).
  • PET findings were adjudged negative for neoplastic localisations in the following instances: physiological uptake (urinary, muscular, thymic or gastrointestinal in patients without MALT), symmetrical nodal uptake, uptake in lesions unrelated to lymphoma that had already been identified by other imaging methods at the time of PET scan, uptake at sites atypical for lymphoma, very low uptake and non-focal uptake.
  • RESULTS: Overall, 354 scans (in 256 patients) showed increased FDG uptake (244 scans in NHL and 110 in HD): in 286 cases, FDG uptake was considered pathological and indicative of ML, in 41 cases the findings were described as uncertain or equivocal and in 37 cases, FDG uptake was considered unrelated to ML (in ten scans, concurrent findings of abnormal FDG uptake attributed to ML and uptake assigned to other causes were obtained) .
  • As already suggested, increased FDG uptake may also be observed in patients without active disease; in most cases, however, non-pathological FDG accumulation is properly identified.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnostic imaging. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma, Non-Hodgkin / diagnostic imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. False Positive Reactions. Female. Humans. Image Processing, Computer-Assisted. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Positron Imaging. 1998 Mar;1(2):101-110 [14516598.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Oct;14 (5):415-26 [12555882.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S128-30 [12692689.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1789-96 [14602861.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):682-8 [12601498.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10 ):1564-78 [11083548.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):888-90 [9189136.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):73-80 [14758137.001]
  • [Cites] Radiographics. 1999 Jan-Feb;19(1):61-77; quiz 150-1 [9925392.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1225-31 [12902411.001]
  • [Cites] Ann Oncol. 2001 May;12 (5):719-22 [11432634.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S117-27 [12748831.001]
  • [Cites] Blood. 2001 Nov 15;98 (10 ):2930-4 [11698273.001]
  • [Cites] Eur J Nucl Med. 1996 Oct;23 (10 ):1409-15 [8781149.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S37-41 [12677306.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S89-96 [12748829.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3347-9 [12149309.001]
  • (PMID = 15785956.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


61. Markou K, Goudakos J, Constantinidis J, Kostopoulos I, Vital V, Nikolaou A: Primary laryngeal lymphoma: report of 3 cases and review of the literature. Head Neck; 2010 Apr;32(4):541-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary laryngeal lymphoma: report of 3 cases and review of the literature.
  • METHODS: The case records of 3 patients with the diagnosis of lymphoma involving the larynx were retrospectively reviewed.
  • RESULTS: The histopathological diagnosis revealed 1 case of marginal zone lymphoma mucosa-associated lymphoid tissue type, 1 case of T-lymphoblastic lymphoma, and 1 case of a rare coexistence of in situ squamous cell carcinoma with an isolated intravascular (angioimmunoblastic) lymphoma of peripheral T-cell origin.
  • CONCLUSIONS: Primary laryngeal lymphoma is a rare entity.
  • Because of the rarity of this tumor type, the optimal management remains controversial and it seems that should be managed not as a distinct disease entity but as an unusual presentation of non-Hodgkin lymphoma, according to the recent treatment trends.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Non-Hodgkin / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Fatal Outcome. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, High-Energy / methods. Risk Assessment. Tracheotomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378323.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


62. Giannini S, Mezzasoma AM, Guglielmini G, Rossi R, Falcinelli E, Gresele P: A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry. Cytometry B Clin Cytom; 2008 May;74(3):194-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A previously healthy 27-year-old male developed severe mucocutaneous bleeding, despite a normal platelet count, associated with non Hodgkin lymphoma.
  • [MeSH-minor] Adult. Autoantibodies / blood. Blood Platelets / immunology. Blood Platelets / metabolism. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Male. Platelet Membrane Glycoproteins / metabolism

  • Genetic Alliance. consumer health - Thrombasthenia.
  • Genetic Alliance. consumer health - Thrombasthenia of Glanzmann and Naegeli.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Clinical Cytometry Society
  • (PMID = 18200593.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Platelet Membrane Glycoproteins
  •  go-up   go-down


63. Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ: Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry; 2010 Nov;81(11):1288-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Progressive Multifocal Leukoencephalopathy (PML) is a demyelinating disease of the brain caused by the polyomavirus JC (JCV) in immunosuppressed people.
  • Of all patients, only two were females including one who had non-Hodgkin's lymphoma and was HIV negative.
  • [MeSH-minor] Adult. Antibodies, Viral / blood. Antiretroviral Therapy, Highly Active. Female. Follow-Up Studies. Humans. Lymphoma, Non-Hodgkin / mortality. Magnetic Resonance Imaging. Male. Middle Aged. Time Factors. Treatment Outcome


64. Hicks ML, Lonial S, Langston A, Flowers C, Roback JD, Smith KJ, Mossavi Sai S, Teagarden D, Hamilton ES, Waller EK, Kaufman J: Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion; 2007 Apr;47(4):629-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN AND METHODS: A total of 135 attempts to collect autologous HPC were studied in 132 unique patients with lymphoid malignancies (non-Hodgkin's lymphoma, multiple myeloma, and Hodgkin's disease).
  • [MeSH-minor] Adult. Aged. Algorithms. Antigens, CD34 / blood. Blood Component Removal / methods. Blood Component Removal / statistics & numerical data. Cohort Studies. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / therapy. Time Factors

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Transfusion. 2007 May;47(5):952. Kaufman, Jonathan [added]
  • (PMID = 17381621.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


65. Gorsane I, Bourkhis L, Laatiri MA, Aloui S, Letaif A, Haouala F, Ben Dhia N, Frih A, Zakhama A, Elmay M, Skhiri H: [Acute renal failure caused by renal lymphoma. A case report]. Nephrol Ther; 2010 Apr;6(2):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute renal failure caused by renal lymphoma. A case report].
  • [Transliterated title] Insuffisance rénale aiguë révélatrice d'un lymphome rénal. A propos d'un cas.
  • Acute renal failure, as the initial manifestation of lymphoma, has been reported only in a few cases.
  • A diagnosis of diffuse large B-cell type non-Hodgkin lymphoma was made.
  • However, investigations revealed the presence of two others sites of lymphoma: gastric and ophthalmic.
  • The patient's renal function and kidney size as well as the other lymphoma locations were normalized after the initiation of chemotherapy.
  • [MeSH-major] Acute Kidney Injury / etiology. Eye Neoplasms / diagnosis. Kidney Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Neoplasms, Multiple Primary / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD20 / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Diagnosis, Differential. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20299297.001).
  • [ISSN] 1872-9177
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Biomarkers, Tumor
  •  go-up   go-down


66. Troussard X, Duchenet V, Cornet E, Mouchel D, Malet M, Collignon A: [Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004]. Rev Epidemiol Sante Publique; 2009 Jun;57(3):151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We extracted the data from the "Registre régional des hémopathies malignes de Basse-Normandie (RRHMBN)", a French registry which belongs to the Association of the French Cancer Registries (FRANCIM).
  • In men, the more frequent malignant disorders were non-Hodgkin's malignant lymphomas (NHML) followed by chronic lymphocytic leukemia and other mature neoplasms, myelodysplastic syndromes (MDS), multiple myeloma (MM), myeloproliferative disorders (MPD), acute myeloid leukemias (AML), Hodgkin's lymphomas (HL), Waldenström's macroglobulinemia (WM) and acute lymphoblastic leukemia (ALL).
  • In women, MM is the third more frequent haematological disorders after NHML and lymphocytic leukaemia and other mature neoplasms, MPD, MDS, AML, Hodgkin's lymphomas, WM and ALL.
  • We provide the incidence for the main haematological disorders and for the first time we also present the incidence of the different subtypes of the Hodgkin's and non-Hodgkin's malignant lymphomas, mature lymphoid neoplasms, MPD and also MDS.
  • [MeSH-minor] Adult. Aged. Algorithms. Female. France / epidemiology. Hodgkin Disease / epidemiology. Humans. Incidence. International Classification of Diseases / statistics & numerical data. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Medical Records. Middle Aged. Multiple Myeloma / epidemiology. Myelodysplastic Syndromes / epidemiology. Myeloproliferative Disorders / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Retrospective Studies. Waldenstrom Macroglobulinemia / epidemiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375876.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'épidémiologie et de santé publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


67. Safi S, Kassmaoui H, Hassikou H, Alami M, Homadi A, Tabache F, Baaj M, Hadri L: [Primary non-Hodgkin's lymphoma of the adrenals. A case report]. Ann Endocrinol (Paris); 2007 Jun;68(2-3):208-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the adrenals. A case report].
  • [Transliterated title] Lymphome malin non hodgkinien primitif de la surrénale. A propos d'un cas.
  • Bilateral primary non-Hodgkin's lymphoma (NHL) of the adrenals is uncommon.
  • The symptoms of disease are variable and depend on the tumor size and the presence of adrenal insufficiency .
  • We report a case of large diffuse B-cell adrenal lymphoma discovered in a 40-year-old woman presenting bilateral lumbar pain.
  • Percutaneous CT-guided biopsy of the adrenal and search for extension revealed primary bilateral adrenal lymphoma.
  • The diagnosis of primary adrenal non-Hodgkin lymphoma should be investigated in patients with a rapidly growing bilateral adrenal mass associated with adrenal insufficiency.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Prednisone / therapeutic use. Shock, Septic / etiology. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531185.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


68. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M: Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol; 2005 Oct 20;23(30):7565-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
  • PURPOSE: This study is an integrated efficacy analysis of the five clinical trials of tositumomab and iodine-131 tositumomab in patients with relapsed or refractory low-grade, follicular, or transformed low-grade non-Hodgkin's lymphoma (NHL) that resulted in the regulatory approval of the iodine-131 tositumomab by the US Food and Drug Administration.
  • The durable response population had many poor prognostic characteristics, including bone marrow involvement (41%), bulky disease > or = 5 cm (49%), and transformed histology (23%).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Follicular / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Resistance, Neoplasm. Female. Humans. Iodine Radioisotopes / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / immunology. Lymphoma, Mantle-Cell / radiotherapy. Male. Middle Aged. Remission Induction. Salvage Therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186600.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes; 0 / iodine-131 anti-B1 antibody
  •  go-up   go-down


69. Song HH, Chen BA, Ding JH, Sun XM, Gao C, Sun YY, Wang J, Cheng J, Zhao G: [Effect of hematopoietic stem cell transplantation in malignant hematologic disease of lymphatic system]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):945-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of hematopoietic stem cell transplantation in malignant hematologic disease of lymphatic system].
  • Through observing 8 patients with non-Hodgkin's lymphoma (NHL) and 3 patients with lymphoblastic leukemia, who received auto or allo-HSCT after chemotherapy, the hematopoietic reconstitution, complication and survival time were evaluated.

  • Genetic Alliance. consumer health - Lymphatic Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096894.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


70. Al-Khayat H, Al-Khayat H, Al-Baker O, Groof A, Sadeq A, Hayati H, Zarka ZA: Cervical radiculopathy secondary to Hodgkin's lymphoma. Surg Neurol; 2007 May;67(5):540-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical radiculopathy secondary to Hodgkin's lymphoma.
  • BACKGROUND: Spinal cord/root compression is a rare complication of HL and usually seen in the setting of progressive, advanced disease.
  • This case report represents a case of HL presenting with epidural disease, with nerve root compression as the only apparent site of clinical involvement.
  • Based on a review of the literature, Hodgkin's disease involving the spinal epidural space is very responsive to chemoradiotherapy with good prognosis for both functional recovery and complete response.
  • CONCLUSION: Chemoradiotherapy is a successful treatment for Hodgkin's disease presenting with spinal root compression.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / pathology. Radiculopathy / etiology. Radiculopathy / pathology. Spinal Nerve Roots / pathology
  • [MeSH-minor] Adult. Cervical Vertebrae / pathology. Drug Therapy. Epidural Space / pathology. Epidural Space / physiopathology. Female. Humans. Magnetic Resonance Imaging. Neck Pain / etiology. Neck Pain / pathology. Neck Pain / physiopathology. Paresthesia / etiology. Paresthesia / pathology. Paresthesia / physiopathology. Radiotherapy. Spinal Canal / pathology. Spinal Canal / physiopathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445629.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kasahara S, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Yamada T, Sawada M, Takahashi T, Moriwaki H: [Clinical effects of biapenem on febrile neutropenia in patients with hematological malignancy]. Jpn J Antibiot; 2008 Jun;61(3):115-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The underlying diseases were acute lymphocytic leukemia in 6 cases, acute myelocytic leukemia in 21, multiple myeloma in 3, and non-Hodgkin's lymphoma in 19.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Leukemia, Myeloid, Acute / complications. Lymphoma, Non-Hodgkin / complications. Multiple Myeloma / complications. Neutropenia / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Thienamycins / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fever / drug therapy. Humans. Injections, Intravenous. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814798.001).
  • [ISSN] 0368-2781
  • [Journal-full-title] The Japanese journal of antibiotics
  • [ISO-abbreviation] Jpn J Antibiot
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Thienamycins; 120410-24-4 / biapenem
  •  go-up   go-down


72. Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM: HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis; 2006 Nov 1;43(9):1198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After a mean follow-up duration of 21 months, 7 patients (28%) received a diagnosis of a malignancy (multiple myeloma, in 1 patient; non-Hodgkin lymphoma, in 1; Hodgkin lymphoma, in 1; Kaposi sarcoma, in 2; and plasmacytoma, in 2).
  • [MeSH-minor] Adult. Aged. Antiretroviral Therapy, Highly Active / adverse effects. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Lymphoma, AIDS-Related / complications. Male. Middle Aged. Retrospective Studies. Sarcoma, Kaposi / complications


73. Herrlinger U, Hebart H, Kanz L, Dichgans J, Weller M: Relapse of primary CNS lymphoma after more than 10 years in complete remission. J Neurol; 2005 Nov;252(11):1409-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of primary CNS lymphoma after more than 10 years in complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Humans. Male. Methotrexate / therapeutic use. Procarbazine / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jul 1;102(1):324-7 [12649152.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1745-53 [9164181.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1356-9 [6616403.001]
  • [Cites] Neurology. 2000 Apr 25;54(8):1707-8 [10762527.001]
  • [Cites] Ann Hematol. 2003 Nov;82(11):712-3 [12961033.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):626-32 [14628129.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1789-93 [12685833.001]
  • (PMID = 15895304.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


74. Bartsch K, Al-Ali H, Reinhardt A, Franke C, Hudecek M, Kamprad M, Tschiedel S, Cross M, Niederwieser D, Gentilini C: Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used. Transplantation; 2009 Jan 27;87(2):217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adult Stem Cells / drug effects. Bone Marrow Transplantation. Leukemia / surgery. Lymphoma, Non-Hodgkin / surgery. Mesenchymal Stem Cell Transplantation. Mesenchymal Stromal Cells / drug effects. Myeloablative Agonists / therapeutic use. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Cell Culture Techniques. Cell Proliferation / drug effects. Cell Separation. Female. Histocompatibility Testing. Humans. Immunophenotyping. Male. Middle Aged. Time Factors. Transplantation Chimera. Transplantation, Homologous. Young Adult


75. Huang HQ, Cai QQ, Lin XB, Wang BF, Bu Q, Gao Y, Peng YL: [Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation]. Ai Zheng; 2007 Apr;26(4):390-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Administration, Cutaneous. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / adverse effects. Carmustine / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cytarabine / adverse effects. Cytarabine / therapeutic use. Female. Humans. Lymphoma, Non-Hodgkin / therapy. Male. Melphalan / adverse effects. Melphalan / therapeutic use. Middle Aged. Pain Measurement. Podophyllotoxin / adverse effects. Podophyllotoxin / therapeutic use. Quality of Life. Transplantation, Homologous / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. FENTANYL .
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430658.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 04079A1RDZ / Cytarabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; UF599785JZ / Fentanyl; BEAM protocol
  •  go-up   go-down


76. Laudi N, Arora M, Burns LJ, Miller JS, McGlave PB, Barker JN, Ramsay NK, Orchard PJ, Macmillan ML, Weisdorf DJ: Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant; 2005 Feb;11(2):129-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
  • Autologous hematopoietic stem cell transplantation (AHSCT) in low-grade non-Hodgkin lymphoma (NHL) can result in a prolonged remission, although most patients eventually relapse and die of their disease.
  • At transplantation, 62 patients (92%) were in complete remission (CR) (6%) or partial remission (PR) (86%); 5 (8%) had resistant disease; and 9 (14%) had transformed to a higher-grade NHL.
  • Recurrent lymphoma after AHSCT remains the major problem, and prolonged survival is further tempered by a significant risk of post-transplantation second malignancies, including myelodysplastic syndrome/acute myeloid leukemia and solid tumors.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / mortality. Male. Middle Aged. Myelodysplastic Syndromes / etiology. Myelodysplastic Syndromes / mortality. Recurrence. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682074.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Huang B, Li CQ, Liu T, Zhou Y: Primary non-Hodgkin's lymphoma of the lumbar vertebrae mimicking tuberculous spondylitis: a case report. Arch Orthop Trauma Surg; 2009 Dec;129(12):1621-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the lumbar vertebrae mimicking tuberculous spondylitis: a case report.
  • Primary non-Hodgkin lymphoma (PHL) of the spine is very rare.
  • After surgical decompression and biopsy, the patient was confirmed as primary B-cell non-Hodgkin lymphoma of the lumbar vertebrae and was further treated with chemotherapy.
  • [MeSH-major] Lumbar Vertebrae. Lymphoma, B-Cell / diagnosis. Spinal Neoplasms / diagnosis. Tuberculosis, Spinal / diagnosis
  • [MeSH-minor] Adult. Diagnostic Errors. Female. Humans

  • Genetic Alliance. consumer health - Spondylitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19221772.001).
  • [ISSN] 1434-3916
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Metzger ML, Hudson MM, Krasin MJ, Wu J, Kaste SC, Kun LE, Sandlund JT, Howard SC: Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer; 2010 Sep 15;116(18):4376-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients.
  • BACKGROUND: Pediatric Hodgkin lymphoma (HL) is a highly curable disease; however, prognostic factors for the survival of patients who develop recurrent disease have not been clearly defined.
  • Fifteen patients developed progressive disease during therapy, 14 patients relapsed early, and 21 patients relapsed late.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • [Cites] J Clin Oncol. 1993 Apr;11(4):704-11 [8478664.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1137-45 [8443375.001]
  • [Cites] Radiology. 1997 Jun;203(3):795-800 [9169707.001]
  • [Cites] Radiology. 1998 Feb;206(2):475-81 [9457202.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):289-95 [9602263.001]
  • [Cites] Bone Marrow Transplant. 1998 Aug;22(3):265-71 [9720740.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3101-9 [10506605.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4532-40 [15542804.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Nov;26(11):740-5 [15543009.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):363-72 [16042685.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6181-9 [16135485.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] Haematologica. 2006 Apr;91(4):475-81 [16585014.001]
  • [Cites] Haematologica. 2006 Apr;91(4):482-9 [16585015.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):189-95 [16601441.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):759-67 [16871391.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72 [17084370.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):60-7 [17021808.001]
  • [Cites] Radiology. 2007 Jul;244(1):257-62 [17581905.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):230-42 [17591570.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Blood. 2001 Jan 15;97(2):404-9 [11154216.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:112-6 [12078891.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3081-7 [12118021.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2026-33 [12743158.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Br J Haematol. 1992 Jun;81(2):197-202 [1643017.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):100-8 [8418221.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2351-61 [8246024.001]
  • (PMID = 20564743.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-78224; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R37 CA036401-24; United States / NCI NIH HHS / CA / CA-60419; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA078224-10; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; None / None / / R01 CA051001-15; United States / NCI NIH HHS / CA / CA-36401; United States / NIGMS NIH HHS / GM / GM061393-100007; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA036401-24; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA078224-10; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA036401; United States / NIGMS NIH HHS / GM / U01 GM061393-100007; United States / NIGMS NIH HHS / GM / GM-61393; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS189726; NLM/ PMC2936658
  •  go-up   go-down


79. Avilés A, Neri N, Nambo JM, Huerta-Guzman J, Talavera A, Cleto S: Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma; 2005 Jul;46(7):1023-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
  • Anthracyclines are a group of drugs that are useful in the treatment of Hodgkin's disease, but have been associated with severe, and in some cases lethal, cardiac toxicity.
  • Four hundred and seventy-six patients with Hodgkin's disease, stages III and IV, were randomly assigned to receive ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) compared with EBVD (epirubicin instead of doxorubicin) and MBVD (mitoxantrone instead of doxorubicin) at standard doses.
  • Thus, we would not recommend use of the drug in Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Heart / drug effects. Heart Diseases / chemically induced. Hodgkin Disease / drug therapy. Mitoxantrone / adverse effects
  • [MeSH-minor] Adolescent. Adult. Bleomycin / adverse effects. Dacarbazine / adverse effects. Disease-Free Survival. Doxorubicin / adverse effects. Echocardiography. Epirubicin / adverse effects. Female. Gated Blood-Pool Imaging. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Survival Rate. Treatment Outcome. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019553.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; ABVD protocol; EBVD protocol
  •  go-up   go-down


80. Hulsman CA, Langerhorst CT: Reversible tonic pupils. J Neuroophthalmol; 2007 Dec;27(4):308-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 36-year-old man with a remote history of Hodgkin lymphoma and a recent history of non-Hodgkin lymphoma (NHL) developed tonic pupils and absent deep tendon reflexes in the lower extremities.
  • [MeSH-minor] Adult. Humans. Lymphoma, Non-Hodgkin / complications. Male

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090568.001).
  • [ISSN] 1070-8022
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Muthalib A, Sukrisman L: Lymphomatous cells in pleural effusion. Acta Med Indones; 2005 Jul-Sep;37(3):173
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Pleural Effusion / pathology
  • [MeSH-minor] Adult. Centrifugation. Cytological Techniques. False Negative Reactions. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110177.001).
  • [ISSN] 0125-9326
  • [Journal-full-title] Acta medica Indonesiana
  • [ISO-abbreviation] Acta Med Indones
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Indonesia
  •  go-up   go-down


82. Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A, German Hodgkin Study Group: Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol; 2008 Jan 20;26(3):434-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
  • PURPOSE: Lymphocyte-predominant Hodgkin's lymphoma (LPHL) is rare and differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • To shed more light on the prognosis and outcome of LPHL, we reviewed all LPHL patients registered in the German Hodgkin Study Group (GHSG) database, comparing patient characteristics and treatment outcome with cHL patients.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Humans. Middle Aged. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Jul;5(7):368-9 [18542117.001]
  • (PMID = 18086799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Sonmez M, Erkut N, Ucar F, Buruk K, Cobanoglu U, Bahce M, Ural AU: Familial Hodgkin's lymphoma from the perspective of HLA. Intern Med; 2010;49(6):607-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial Hodgkin's lymphoma from the perspective of HLA.
  • Although the incidence of Hodgkin lymphoma (HL)--a lymphoid tissue malignity--increases in the presence of several viruses, particularly EBV, as well as with autoimmune diseases and following transplantation, although to date, the exact etiopathogenesis is not known.
  • In this case presentation, the associations between HLs diagnosed in a father of consanguineous marriage and his two children and HLAs in other family members were investigated and the findings are discussed in view of the published literature; no direct association was found between HLA alleles and the development of the disease in the present case with familial HL.
  • [MeSH-major] HLA Antigens / genetics. Hodgkin Disease / genetics. Hodgkin Disease / immunology
  • [MeSH-minor] Adolescent. Adult. Alleles. Consanguinity. Female. Haplotypes / genetics. Humans. Male. Pedigree. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20228601.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Number-of-references] 15
  •  go-up   go-down


84. Han HS, Escalón MP, Hsiao B, Serafini A, Lossos IS: High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol; 2009 Feb;20(2):309-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.
  • BACKGROUND: Positron emission tomography (PET) is a powerful predictor of relapse and survival in non-Hodgkin's lymphomas (NHLs) based on studies carried out in the prerituximab era.
  • RESULTS: In all, 51 patients (diffuse large B cell-38; mantle cell lymphoma-13) treated with rituximab-containing regimens were included.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4652-61 [15837965.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):759-67 [16871391.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Haematologica. 2000 Jun;85(6):613-8 [10870118.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):543-53 [11342337.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1356-63 [12196360.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):682-8 [12601498.001]
  • [Cites] Acta Med Austriaca. 2003;30(2):41-7 [12752087.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):850-4 [15266320.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1524-9 [15946979.001]
  • (PMID = 18842613.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2733066
  •  go-up   go-down


85. Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A: Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev; 2006 Dec;15(12):2348-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: High body mass index (BMI) and diabetes have been linked to risk of non-Hodgkin's lymphoma (NHL), but results are inconsistent and most studies use self-reported information.
  • [MeSH-major] Hematologic Neoplasms / metabolism. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Adult. Blood Glucose / metabolism. Body Mass Index. Female. Humans. Leukemia / metabolism. Leukemia / mortality. Male. Middle Aged. Multiple Myeloma / metabolism. Multiple Myeloma / mortality. Prospective Studies. Risk Factors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164355.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01-HL 03387; United States / NHLBI NIH HHS / HL / R01-HL 15174; United States / NHLBI NIH HHS / HL / R01-HL 21010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


86. Glotzbecker MP, Kersun LS, Choi JK, Wills BP, Schaffer AA, Dormans JP: Primary non-Hodgkin's lymphoma of bone in children. J Bone Joint Surg Am; 2006 Mar;88(3):583-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone in children.
  • BACKGROUND: Primary non-Hodgkin's lymphoma of bone, often more simply referred to as primary lymphoma of bone, is a rare subset of non-Hodgkin's lymphoma in children.
  • There are only a few small series of primary lymphoma of bone in children with long-term follow-up, and none have appeared in the orthopaedic literature.
  • METHODS: A review of our institution's Pediatric Tumor Registry identified fifteen cases of primary lymphoma of bone among 306 cases of diagnosed non-Hodgkin's lymphoma between 1970 and 2003.
  • Five patients died: three of disease progression, one of treatment-related complications, and one of an unrelated cause.
  • CONCLUSIONS: On the basis of the present series and a comprehensive review of similar series in the literature involving patients with primary lymphoma of bone, it appears that younger age, advanced-stage disease, multiple-bone involvement, and non-large-cell histology are associated with decreased survival as compared with older age, localized disease, single-bone involvement, and large-cell histology, respectively.
  • [MeSH-major] Bone Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510826.001).
  • [ISSN] 0021-9355
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Toda K, Shibuya H, Hayashi K, Ayukawa F: Radiation-induced cancer after radiotherapy for non-Hodgkin's lymphoma of the head and neck: a retrospective study. Radiat Oncol; 2009;4:21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced cancer after radiotherapy for non-Hodgkin's lymphoma of the head and neck: a retrospective study.
  • BACKGROUND: survivors of non-Hodgkin's lymphoma (NHL) are well known to be at an increased risk of second malignancies.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Young Adult


88. Sandlund JT: Should adolescents with NHL be treated as old children or young adults? Hematology Am Soc Hematol Educ Program; 2007;:297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should adolescents with NHL be treated as old children or young adults?
  • The SEER (Surveillance, Epidemiology, and End Results) data for the years 1975-1998 show that children with non-Hodgkin lymphoma (NHL) have a better treatment outcome than do adults.
  • The spectrum of NHL subtypes is well known to differ in children and adults.
  • From ages 5 through 14 years, Burkitt lymphoma is the predominant histologic subtype, whereas diffuse large B-cell lymphoma is most common in the 15- to 29-year age range.
  • Because different treatment strategies are often used in children and adults with NHL, the choice of therapy for adolescents and young adults (ages 15 through 29 years) is challenging and somewhat controversial.
  • It is reasonable to consider pediatric strategies for some adolescents and very young adults with NHL, and pediatric strategies are currently used to treat adults with certain subtypes of NHL (Burkitt lymphoma, lymphoblastic lymphoma).
  • However, the use of pediatric strategies in adults does not guarantee a comparable outcome, as illustrated by trials for adult lymphoblastic lymphoma.
  • There is clearly a need for further biologic study of NHL in children, adolescents, and young adults.
  • Age-related differences in tumor biology have been demonstrated in anaplastic large-cell lymphoma (ALCL) and diffuse large B-cell lymphoma (DLBCL).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024643.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 62
  •  go-up   go-down


89. King RL, Pasha T, Roullet MR, Zhang PJ, Bagg A: IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Hum Pathol; 2009 Dec;40(12):1699-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IMP-3 is a member of the insulin-like growth factor II mRNA binding protein (IMP) family of proteins that play a role in RNA trafficking and stabilization and cell growth and migration during embryogenesis but which are down-regulated in adult tissue.
  • Among lymphoid neoplasms, Hodgkin lymphoma demonstrated the highest percentage of positive cases (26/26, 100%) often with bright staining.
  • Burkitt lymphoma was positive in 10 (83%) of 12 cases with moderate to bright staining.
  • Although follicular lymphoma was also positive in a high percentage of cases (12/15, 80%), the intensity was exclusively weak to moderate.
  • By contrast, lower proportions (8%-20%) of other non-germinal center B lymphoma subtypes were IMP-3-positive.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphoid Tissue / metabolism. Lymphoma / metabolism. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698973.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


90. Rathi S, Shakir F, Sech C, Lazzara R: Non-hodgkin lymphoma causing acute myocardial infarction and tachyarrhythmia. Am J Cardiol; 2009 Aug 1;104(3):450-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-hodgkin lymphoma causing acute myocardial infarction and tachyarrhythmia.
  • [MeSH-major] Heart Neoplasms / secondary. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / pathology. Myocardial Infarction / etiology. Tachycardia / etiology
  • [MeSH-minor] Adult. African Americans. Electrocardiography. Female. Heart Conduction System. Humans. Myocardium. Neoplasm Staging


91. Goldblum D, Ghadjar P, Curschmann J, Greiner R, Aebersold D: Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Radiat Oncol; 2008;3:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Five patients (2 males, 3 females) with diagnosed malignancies (Non-Hodgkin B-cell Lymphoma, neuroendocrine carcinoma) involving the lacrimal gland, in which either combined CT-RT or local RT were indicated, were prophylactically treated with amifostine (500 mg sc).
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Neuroendocrine / radiotherapy. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Male. Middle Aged. Pilot Projects

  • Bern Open Repository and Information System. Free Full text from BORIS .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8):1155-62; discussion 1162-9 [11236308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):739-47 [11849797.001]
  • [Cites] Anticancer Drugs. 2002 Mar;13(3):181-209 [11984063.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):818-23 [12377334.001]
  • [Cites] Arch Ophthalmol. 1969 Jul;82(1):10-4 [4183019.001]
  • [Cites] Am J Ophthalmol. 1991 Jan 15;111(1):106-8 [1985472.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1035-9 [11072160.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] CLAO J. 1995 Oct;21(4):221-32 [8565190.001]
  • [Cites] Ann Oncol. 1998 May;9(5):505-9 [9653491.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1347-55 [17318564.001]
  • [Cites] Strahlenther Onkol. 1999 Nov;175 Suppl 4:30-3 [10584138.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3339-45 [11013273.001]
  • [Cites] J Am Dent Assoc. 1991 Mar;122(3):63-9 [2019691.001]
  • (PMID = 18761746.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  • [Other-IDs] NLM/ PMC2542992
  •  go-up   go-down


92. Simonelli C, Tedeschi R, Gloghini A, Bortolin MT, Spina M, Bidoli E, Cinelli R, De Paoli P, Carbone A, Tirelli U: Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis; 2005 Apr 1;40(7):1022-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy.
  • BACKGROUND: Primary effusion lymphoma (PEL) represents a peculiar lymphoma infected with human herpesvirus 8 (HHV-8) and occurs predominantly in human immunodeficiency virus (HIV)-infected patients.
  • The aim of the present study was to evaluate the immunologic and virological parameters, including HHV-8 viremia, of 5 HIV-infected patients with PEL whose disease was diagnosed and treated at our institute.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / immunology. HIV Infections / virology. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Anti-HIV Agents. CD4 Lymphocyte Count. Disease Progression. Female. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Humans. Male. Viral Load. Viral Proteins / metabolism. Viremia


93. Vides Almonacid G, García A, Denninghoff V, Avagnina A, Castiglioni T, Elsner B: [Flow cytometry for the study of mediastinal tumors with abundant lymphoid elements]. Medicina (B Aires); 2008;68(1):43-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La citometría de flujo en el estudio de tumores mediastinales ricos en elementos linfoides.
  • A differential diagnosis can be sometimes made between thymoma and precursor T-lymphoblastic lymphoma (T-LBL).
  • Among 38 mediastinal tumors, we found 6 benign lesions, 9 diffuse large B-cell lymphomas (DLBCL), 10 Hodgkin lymphomas (HL), 11 thymomas and 2 T-LL.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD3 / analysis. Antigens, CD4 / analysis. Antigens, CD8 / analysis. Child. Child, Preschool. Female. Humans. Hyperplasia. Male. Middle Aged. Phenotype. Retrospective Studies. T-Lymphocytes / immunology. Young Adult

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416319.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Biomarkers, Tumor
  •  go-up   go-down


94. Karube K, Ohshima K, Suzumiya J, Kawano R, Kikuchi M, Harada M: Gene expression profile of cytokines and chemokines in microdissected primary Hodgkin and Reed-Sternberg (HRS) cells: high expression of interleukin-11 receptor alpha. Ann Oncol; 2006 Jan;17(1):110-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profile of cytokines and chemokines in microdissected primary Hodgkin and Reed-Sternberg (HRS) cells: high expression of interleukin-11 receptor alpha.
  • We microdissected Hodgkin and Reed-Sternberg (HRS) cells from 14 Hodgkin's lymphoma tissue samples (nodular sclerosis = 5; mixed cellularity = 9), and after isolation and amplification of mRNA, analyzed the expression profile of 140 genes of chemokines, cytokines and their receptors by cDNA microarray methods.
  • In contrast, only few cases were positive for IL-11Ralpha in B cell lymphoma, diffuse large cell lymphoma and follicular lymphoma.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291580.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / IL11RA protein, human; 0 / Interleukin-11 Receptor alpha Subunit; 0 / RNA, Messenger; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-11
  •  go-up   go-down


95. Pérez Bergara E, Pavón Benito A, Lánderer Vázquez T, Salvador Bravo M, Aizcorbe Garralda M, Zugasti O: [Fracture and embolization of implantable subclavian venous catheter fragments due to costoclavicular compression: pinch-off syndrome]. Rev Esp Anestesiol Reanim; 2009 Feb;56(2):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Sección y embolización de catéter permanente por síndrome de pinzamiento costoclavicular (pinch-off).
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Equipment Failure. Female. Humans. Infusions, Intravenous / instrumentation. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thoracic Outlet Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19334661.001).
  • [ISSN] 0034-9356
  • [Journal-full-title] Revista española de anestesiología y reanimación
  • [ISO-abbreviation] Rev Esp Anestesiol Reanim
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 11
  •  go-up   go-down


96. Subramanian R, Solo S, Mishra MM, Murugan P, Siddaraju N, Basu D, Srinivasan R: Fine needle aspiration cytology of primary lymphoid lesions of the orbit: report of four cases. Acta Cytol; 2007 May-Jun;51(3):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two were cytologically diagnosed with low-grade non-Hodgkin lymphoma (NHL) and 2 with pseudolymphoma and inflammatory pseudotumor, respectively.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Orbit / pathology. Orbital Pseudotumor / pathology. Pseudolymphoma / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2007 May-Jun;51(3):367-9 [17536536.001]
  • (PMID = 17536545.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Figueiredo CP, Franz-Vasconcelos HC, Giunta Gd, Mazzuco TL, Caon T, Fernandes AL, Simões CM, Antunes VL, Niel C, Barardi CR: Detection of Torque teno virus in Epstein-Barr virus positive and negative lymph nodes of patients with Hodgkin lymphoma. Leuk Lymphoma; 2007 Apr;48(4):731-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Torque teno virus in Epstein-Barr virus positive and negative lymph nodes of patients with Hodgkin lymphoma.
  • The age-specific incidence of Hodgkin lymphoma (HL) is bimodal with peaks occurring among young adults (15 - 34 years old) and people older than 45 years.
  • However, it was observed that the group of young adults (15 - 34 years, n = 19) showed the lowest EBV frequency (21%) but the highest TTV occurrence (60%).
  • This may suggest an involvement of TTV infection in the pathogenesis of HL in young adults.
  • [MeSH-major] DNA Virus Infections / complications. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / metabolism. Hodgkin Disease / pathology. Hodgkin Disease / virology. Lymph Nodes / virology. Torque teno virus / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Apr;48(4):647-8 [17454618.001]
  • (PMID = 17454631.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


98. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA: Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood; 2008 Jun 1;111(11):5359-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma.
  • To investigate their importance in non-Hodgkin lymphoma (NHL), we enumerated Treg cells in peripheral blood mononuclear cells (PBMCs) and involved tissues from 30 patients.
  • CD25(+)FoxP3(+)CD127(low)CD4(+) Treg cells were increased markedly in PBMCs (median = 20.4% CD4 T cells, n = 20) versus healthy controls (median = 3.2%, n = 13, P < .001) regardless of lymphoma subtype, and correlated with disease stage and serum lactate dehydrogenase (R(s) = 0.79, P < .001).
  • [MeSH-major] Lymphoma, Non-Hodgkin / immunology. T-Lymphocyte Subsets / immunology. T-Lymphocytes, Regulatory / immunology. Tumor Escape / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Flow Cytometry. Humans. Lymphocyte Activation / immunology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18305220.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Klabusay M, Lysák D, Hrabcáková V, Navrátil M, Coupek P, Mayer J: [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation]. Cas Lek Cesk; 2008;147(6):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
  • BACKGROUND: Peripheral blood stem cells are the preferred source for transplantation of hematopoiesis in patients with non-Hodgkin's lymphoma.
  • Authors analyzed the effect of two growth factors (leridistim and filgrastim) on the kinetics and phenotype of CD34+ cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Antigens, CD34 / analysis. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cell Mobilization. Interleukin-3 / pharmacology. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation. Recombinant Fusion Proteins / pharmacology
  • [MeSH-minor] Adult. Female. Filgrastim. Humans. Immunophenotyping. Leukapheresis. Leukocytes / immunology. Male. Middle Aged. Recombinant Proteins. Stem Cells / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724529.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Interleukin-3; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 193700-51-5 / leridistim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


100. Sung HJ, Kim SJ, Seo HY, Sul HR, Choi JG, Choi IK, Park KH, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS: Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Br J Haematol; 2006 Jul;134(1):45-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The important prognostic factors were evaluated for T-cell non-Hodgkin lymphoma (NHL) patients in a prospective study using the CEOP-B protocol [a modified cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like regimen that uses epirubicin instead of doxorubicin with the addition of bleomycin].
  • The factors related to poor outcome were a high International Prognostic Index (IPI) and a high 'B' score (bone marrow involvement, B symptoms, bulky disease).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Bone Marrow Cells / immunology. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Humans. Male. Middle Aged. Neutropenia / etiology. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803566.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP-B protocol
  •  go-up   go-down






Advertisement